Previous Article
Antimicrobial Agents and Chemotherapy, March 1998, p. 727-727, Vol. 42, No. 3
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
LETTERS TO THE EDITOR
Selection of Fluoroquinolone-Resistant Methicillin-Resistant
Staphylococcus aureus with Ciprofloxacin and Trovafloxacin
 |
LETTER |
Resistance to ciprofloxacin in methicillin-resistant
Staphylococcus aureus emerges more rapidly than to
ofloxacin, levofloxacin, or sparfloxacin (1, 2). We compared
emergence of resistance to trovafloxacin with that to ciprofloxacin.
We examined 13 methicillin-resistant S. aureus isolates for
which the ciprofloxacin and trovafloxacin MICs were
1 and
2 µg/ml, respectively, and for which unique genotypes were found by
pulsed-field gel electrophoresis.
Spontaneous single-step mutation rates were determined by growing
bacteria in antibiotic-free broth and plating 0.1-ml aliquots on
Mueller-Hinton agar containing four or eight times the MIC of
ciprofloxacin or trovafloxacin. The resistance frequency was calculated
by dividing the number of colonies at 48 h by the inoculum. The
emergence of resistance during serial transfer was studied by growing
bacteria in antibiotic-free medium, adjusting the cultures to
108 CFU/ml, and spreading 0.2-ml aliquots onto
Mueller-Hinton agar containing twofold dilutions (0.0625 to 32 µg/ml)
of antibiotic. All colonies appearing at 48 h at the highest
antibiotic concentration were collected by swab, regrown in
antibiotic-free medium, and reinoculated onto another set of
antibiotic-containing plates. All experiments were performed in
duplicate. Single-step resistance rates and changes in the MIC with
serial transfer were compared by the Wilcoxon signed rank test
after log transformation of the data. The number of strains developing
single-step resistance was compared by using Fisher's exact
test.
Single-step resistance occurred in all strains exposed to 4× the MIC
of ciprofloxacin but in only 4 (31%) strains exposed to trovafloxacin
(P < 0.05). There was no difference in resistance rates at 8× the MIC of the antibiotics. The mean resistance rates at
4× the MIC of ciprofloxacin and trovafloxacin were 6.8 × 10
7 (range, <2.1 × 10
8 to 3.1 × 10
6) and 8.5 × 10
9 (range,
<3.3 × 10
10 to 1.1 × 10
7),
respectively (P < 0.05) (Table
1).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Single-step resistance rates in 13 methicillin-resistant
S. aureus strains exposed to ciprofloxacin (cipro)
or trovafloxacin (trova)
|
|
In serial transfer experiments, for all strains the mean MIC of
ciprofloxacin increased 6.7 ± 0.9-fold, and the MIC of
trovafloxacin increased 3.3 ± 0.9-fold (P < 0.05). The MICs for all strains exposed to ciprofloxacin increased by
fourfold after a single transfer; the strains became resistant (MIC,
4 µg/ml) (3) within 4 transfers, and the MIC was
32
µg/ml after 10 transfers. In contrast, the MIC was 4 µg/ml for only
one strain exposed to trovafloxacin. The mean MIC for the remaining
strains was 2 µg/ml after 10 transfers.
Single-step resistance and the emergence of resistance with serial
transfer appear to be more common with ciprofloxacin than with
trovafloxacin.
 |
ACKNOWLEDGMENTS |
This work was supported by Pfizer, Inc., New York.
 |
REFERENCES |
| 1.
|
Kang, S. L.,
M. J. Rybak,
B. J. McGrath,
G. W. Kaatz, and S. M. Seo.
1994.
Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.
Antimicrob. Agents Chemother.
38:2702-2709[Abstract/Free Full Text].
|
| 2.
|
Kojima, T.,
M. Inoue, and M. Susumu.
1990.
In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus.
Antimicrob. Agents Chemother.
34:1123-1127[Abstract/Free Full Text].
|
| 3.
|
National Committee for Clinical Laboratory Standards.
1997.
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4.
National Committee for Clinical Laboratory Standards, Villanova, Pa.
|
| | | | |
Martin E. Evans
William B. Titlow
Division of Infectious Diseases Department of Internal Medicine University of Kentucky School of Medicine 800 Rose Street Lexington, KY 40536
|
Antimicrobial Agents and Chemotherapy, March 1998, p. 727-727, Vol. 42, No. 3
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Butler, M. M., LaMarr, W. A., Foster, K. A., Barnes, M. H., Skow, D. J., Lyden, P. T., Kustigian, L. M., Zhi, C., Brown, N. C., Wright, G. E., Bowlin, T. L.
(2007). Antibacterial Activity and Mechanism of Action of a Novel Anilinouracil-Fluoroquinolone Hybrid Compound. Antimicrob. Agents Chemother.
51: 119-127
[Abstract]
[Full Text]
-
Martin, C., Ofotokun, I., Rapp, R., Empey, K., Armitstead, J., Pomeroy, C., Hoven, A., Evans, M.
(2005). Results of an antimicrobial control program at a university hospital. Am J Health Syst Pharm
62: 732-738
[Abstract]
[Full Text]
-
Campion, J. J., McNamara, P. J., Evans, M. E.
(2004). Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments. Antimicrob. Agents Chemother.
48: 4733-4744
[Abstract]
[Full Text]
-
Butler, M. M., Skow, D. J., Stephenson, R. O., Lyden, P. T., LaMarr, W. A., Foster, K. A.
(2002). Low Frequencies of Resistance among Staphylococcus and Enterococcus Species to the Bactericidal DNA Polymerase Inhibitor N3-Hydroxybutyl 6-(3'-Ethyl-4'-Methylanilino) Uracil. Antimicrob. Agents Chemother.
46: 3770-3775
[Abstract]
[Full Text]
-
Vaudaux, P., Francois, P., Bisognano, C., Schrenzel, J., Lew, D. P.
(2002). Comparison of Levofloxacin, Alatrofloxacin, and Vancomycin for Prophylaxis and Treatment of Experimental Foreign-Body-Associated Infection by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother.
46: 1503-1509
[Abstract]
[Full Text]
-
Gootz, T. D., Zaniewski, R. P., Haskell, S. L., Kaczmarek, F. S., Maurice, A. E.
(1999). Activities of Trovafloxacin Compared with Those of Other Fluoroquinolones against Purified Topoisomerases and gyrA and grlA Mutants of Staphylococcus aureus. Antimicrob. Agents Chemother.
43: 1845-1855
[Abstract]
[Full Text]